The Journal of Thoracic and Cardiovascular Surgery
Volume 137, Issue 1 , Pages 43-48 , January 2009

Fluorodeoxyglucose positron emission tomography and tumor marker expression in non–small cell lung cancer

  • Matthew D. Taylor, MD

      Affiliations

    • Department of Surgery, University of Virginia, Charlottesville, Va
    • ,
  • Philip W. Smith, MD

      Affiliations

    • Department of Surgery, University of Virginia, Charlottesville, Va
    • ,
  • William K. Brix, MD

      Affiliations

    • Department of Pathology, University of Virginia, Charlottesville, Va
    • ,
  • Mark R. Wick, MD

      Affiliations

    • Department of Pathology, University of Virginia, Charlottesville, Va
    • ,
  • Nicholas Theodosakis

      Affiliations

    • Department of Surgery, University of Virginia, Charlottesville, Va
    • ,
  • Brian R. Swenson, MD, MS

      Affiliations

    • Department of Surgery, University of Virginia, Charlottesville, Va
    • ,
  • Benjamin D. Kozower, MD

      Affiliations

    • Department of Surgery, University of Virginia, Charlottesville, Va
    • ,
  • Christine L. Lau, MD

      Affiliations

    • Department of Surgery, University of Virginia, Charlottesville, Va
    • ,
  • David R. Jones, MD

      Affiliations

    • Department of Surgery, University of Virginia, Charlottesville, Va
    • Corresponding Author InformationAddress for reprints: David R. Jones, MD, Professor of Surgery, University of Virginia, Department of Surgery, Box 800679, Charlottesville, VA 22908-0679.

Received 24 June 2008 ,Revised 18 September 2008 ,Accepted 13 October 2008.

References 

  1. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose–positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201–3206
  2. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non–small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005;130:151–159
  3. Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non–small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol. 2006;59:790–800
  4. Betticher DC, Heighway J, Hasleton PS, Altermatt HJ, Ryder WD, Cerny T, et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer. 1996;73:294–300
  5. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492–1495
  6. Fujino M, Dosaka-Akita H, Harada M, Hiroumi H, Kinoshita I, Akie K, et al. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer. 1995;76:2457–2463
  7. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Cyclin D1 in non–small cell lung cancer: a key driver of malignant transformation. Lung Cancer. 2007;55:1–14
  8. Kajita T, Ohta Y, Kimura K, Tamura M, Tanaka Y, Tsunezuka Y, et al. The expression of vascular endothelial growth factor C and its receptors in non–small cell lung cancer. Br J Cancer. 2001;85:255–260
  9. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl. 4):S9–S15
  10. Niklinska W, Burzykowski T, Chyczewski L, Niklinski J. Expression of vascular endothelial growth factor (VEGF) in non–small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis. Lung Cancer. 2001;34(Suppl. 2):S59–S64
  11. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992;52:4828–4831
  12. Sunaga N, Oriuchi N, Kaira K, Yanagitani N, Tomizawa Y, Hisada T, et al. Usefulness of FDG–PET for early prediction of the response to gefitinib in non–small cell lung cancer. Lung Cancer. 2008;59:203–210
  13. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989;246:491–494
  14. Lagendijk JH, Mullink H, van Diest PJ, Meijer GA, Meijer CJ. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. J Clin Pathol. 1999;52:283–290
  15. Al-Sugair A, Coleman RE. Applications of PET in lung cancer. Semin Nucl Med. 1998;28:303–319
  16. Ahuja V, Coleman RE, Herndon J, Patz EF. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998;83:918–924
  17. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997;80:1046–1051
  18. de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer. 2007;55:79–87
  19. van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non–small cell lung cancer. Eur J Cancer. 2007;43:1392–1398
  20. Nguyen XC, So Y, Chung JH, Lee WW, Park SY, Kim SE. High correlations between primary tumours and loco–regional metastatic lymph nodes in non-small-cell lung cancer with respect to glucose transporter type 1-mediated 2-deoxy-2-F18-fluoro-d-glucose uptake. Eur J Cancer. 2008;44:692–698
  21. Tanaka F, Yanagihara K, Otake Y, Li M, Miyahara R, Wada H, et al. Biological features and preoperative evaluation of mediastinal nodal status in non–small cell lung cancer. Ann Thorac Surg. 2000;70:1832–1838
  22. Sunaga N, Tomizawa Y, Yanagitani N, Iijima H, Kaira K, Shimizu K, et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non–small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer. 2007;56:383–389
  23. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi H, Angeletti CA, et al. Epidermal growth factor receptor (EGFr) expression in non–small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer. 1995;31A:178–183
  24. Watanabe K, Nomori H, Ohtsuka T, Naruke T, Ebihara A, Orikasa H, et al. [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. Jpn J Clin Oncol. 2006;36:403–409
  25. Keum JS, Kong G, Yang SC, Shin DH, Park SS, Lee JH, et al. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non–small cell lung cancer. Br J Cancer. 1999;81:127–132
  26. Bremnes RM, Camps C, Sirera R. Angiogenesis in non–small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 2006;51:143–158
  27. Yuan A, Yu CJ, Chen WJ, Lin FY, Kuo SH, Luh KT, et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer. 2000;89:475–483
  28. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer. 2003;97:457–464
  29. Ogawa E, Takenaka K, Yanagihara K, Kurozumi M, Manabe T, Wada H, et al. Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non–small cell lung cancer patients. Br J Cancer. 2004;91:498–503
  30. Takizawa H, Kondo K, Fujino H, Kenzaki K, Miyoshi T, Sakiyama S, et al. The balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node metastasis in non–small cell lung cancer. Br J Cancer. 2006;95:75–79

 Read at the Thirty-fourth Annual Meeting of The Western Thoracic Surgical Association, Kona, Hawaii, June 25–28, 2008.

PII: S0022-5223(08)01725-X

doi: 10.1016/j.jtcvs.2008.10.014

The Journal of Thoracic and Cardiovascular Surgery
Volume 137, Issue 1 , Pages 43-48 , January 2009

Article Tools

* Image Usage & Resolution